| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) o
- The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) o (en)
- Autoři předkládají 8 leté zkušenosti nerandomizované studie zkoumající zda dexrazoxane (ICRF-187) může snížit anthracyklinem indukovanou kardiotoxicitu u pacientů léčených v dětství pro hematologickou malignitu. Autoři prospektivně vyšetřili soubor 75 pacientů (40mužů/35 žen) ve věku 2-17 let ( median 67,5 let) v době prezentace diagnozy. Kardioprotekce byla podána 53 pacientům (26mužům/17 ženám) a standardní protokol byl použit u 22 pacientů (14 mužů/8 ženám) Prospektivní echokardiografické vyšetření bylo provedeno před a po chemoterapii a následně každý rok sledovacího období.Dynamická stress echokardiografie byla provedena v posledním roce.Vyšší kumulativní dávky anthracyklinu byly podány v dexrazonové skupině (234+58mg/m2, median 240mg/m2, versus 203+86mg/m2, median 210mg/m2, P < 0.04) a signifikantně vyšší procento pacientů obdrželo kumulativní dávku >240mg/m2 anthracyclinu ( P<0.05). Během sledování frakcionované zkrácení (FS) pokleslo ve skupině bez bez dexrazoxanu jen (cs)
|
| Title
| - Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
- Dlouhodobé pravidelné echokardiografické vyšetření pozdní antracyklinové toxicity a jeho prevence dexrazonem u dětských pacientů (cs)
- Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients (en)
|
| skos:prefLabel
| - Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
- Dlouhodobé pravidelné echokardiografické vyšetření pozdní antracyklinové toxicity a jeho prevence dexrazonem u dětských pacientů (cs)
- Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients (en)
|
| skos:notation
| - RIV/00843989:_____/05:00100053!RIV09-MSM-00843989
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(NR8006), Z(MSM0021622402)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00843989:_____/05:00100053
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - anthracycline; cardiotoxicity; children; dexrazoxane (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - DE - Spolková republika Německo
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - European journal of pediatrics
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Blažek, Bohumír
- Hrstková, H.
- Michálek, J.
- Elbl, L.
- Tomášková, I.
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)